Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 168 epcoritamab plus R-mini-CHOP versus R-mini-CHOP in frail untreated DLBCL
NL-OMON61542Phase 2Not yet recruiting
- Sponsor
- HOVON
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and follicular lymphoma, transformed (t-FL) (2 arms), sponsored by HOVON. Primary endpoints: Complete remission and Progression-free survival. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma, transformed (t-FL)
Beyond the preview
Go deeper on NL-OMON61542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61542.